Neratinib
Neratinib is an oral targeted anticancer medicine used to treat certain forms of HER2-positive breast cancer, including extended adjuvant treatment following trastuzumab-based therapy and, in some regions, advanced or metastatic disease in combination with other medicines. It works by irreversibly inhibiting HER2 and other epidermal growth factor receptor family tyrosine kinases, blocking signalling pathways involved in cancer cell growth and survival. Neratinib is available as oral tablets, with treatment duration and combination regimens determined by the approved indication and oncology protocol. Diarrhoea is a particularly common adverse effect and may be severe; other side effects include nausea, vomiting, abdominal discomfort, fatigue, and rash. The medicine can also cause liver toxicity, so liver function monitoring and preventive diarrhoea management are important during treatment. Neratinib should be prescribed and monitored by an oncologist, with careful review of drug interactions and pregnancy-related precautions.
Neratinib was historically used as a respiratory medicine for the symptomatic management of certain respiratory conditions. Its former uses included:
is okay
The import of medicines into India is regulated by the Central Drugs Standard Control Organisation (CDSCO) under the Drugs and Cosmetics Act, 1940, and the Drugs and Cosmetics Rules, 1945. The regulatory requirements depend on whether the product is an active pharmaceutical ingredient (API), a finished formulation, or an unapproved medicine intended for an individual patient's treatment.
Primeera Healthcare Private Limited can provide import coordination and pharmaceutical documentation assistance for Neratinib, subject to confirmation of its current regulatory status and eligibility for import into India.
The export of Neratinib from India is subject to applicable requirements under the Drugs and Cosmetics Act, 1940, the Drugs and Cosmetics Rules, 1945, and relevant export, customs, and destination-country regulations. Documentation requirements depend on whether the product is an active pharmaceutical ingredient (API), a finished pharmaceutical formulation, or a medicine intended for a specific market. Export eligibility and destination-country requirements must be verified before shipment.
Primeera Healthcare Private Limited can provide pharmaceutical export documentation assistance, regulatory coordination, and shipping support for Neratinib, subject to confirmation of its export eligibility under applicable Indian regulations and the import requirements of the destination country.
If you have any questions or need any help, contact our Support Team. We will get in touch with you within 24 hours from Monday to Friday between 9:00 and 10:00 CET.
All Trademarks and Brands that appear on the website belong to their respective owners. Primeera Healthcare does not lay any claim on them; we only provide information.
